Literature DB >> 20695008

Human prion strain selection in transgenic mice.

Kurt Giles1, David V Glidden, Smita Patel, Carsten Korth, Darlene Groth, Azucena Lemus, Stephen J DeArmond, Stanley B Prusiner.   

Abstract

OBJECTIVE: Transgenic (Tg) mice expressing chimeras of mouse and human prion proteins (PrPs) have shorter incubation periods for Creutzfeldt-Jakob disease (CJD) prions than mice expressing full-length human PrP. Increasing the sequence similarity of the chimeric PrP to mouse PrP, by reverting human residues to mouse, resulted in a Tg line, denoted Tg22372, which was susceptible to sporadic (s) CJD prions in approximately 110 days.
METHODS: Mice expressing chimeric mouse/human PrP transgenes were produced. The mice were inoculated intracerebrally with extracts prepared from the brains of patients who died of CJD. Onset of neurological dysfunction marked the end of the incubation time. After sacrifice of the Tg mice, their brains were analyzed for PrP(Sc) and neuropathological changes.
RESULTS: Reversion of 1 additional residue (M111V) resulted in a new Tg line, termed Tg1014, susceptible to sCJD prions in approximately 75 days. Tg1014 mice also have shorter incubation periods for variant (v) CJD prions, providing a more tractable model for studying this prion strain. Transmission of vCJD prions to Tg1014 mice resulted in 2 different strains, determined by neuropathology and biochemical analysis, which correlated with the length of the incubation time. One strain had the biochemical, neuropathological, and transmission characteristics, including longer incubation times, of the inoculated vCJD strain; the second strain produced a phenotype resembling that of sCJD prions including relatively shorter incubation periods. Mice with intermediate incubation periods for vCJD prions had a mixture of the 2 strains. Both strains were serially transmitted in Tg1014 mice, which led to further reduction in incubation periods. Conversion of vCJD-like to sCJD-like strains was favored in Tg1014 mice more than in the Tg22372 line. The single amino acid difference therefore appears to offer selective pressure for propagation of the sCJD-like strain.
INTERPRETATION: These 2 Tg mouse lines provide relatively rapid models to study human prion diseases as well as the evolution of human prion strains.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20695008      PMCID: PMC2935907          DOI: 10.1002/ana.22104

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  52 in total

1.  Conformational variations in an infectious protein determine prion strain differences.

Authors:  Motomasa Tanaka; Peter Chien; Nariman Naber; Roger Cooke; Jonathan S Weissman
Journal:  Nature       Date:  2004-03-18       Impact factor: 49.962

2.  Evidence that the transmission of one source of scrapie agent to hamsters involves separation of agent strains from a mixture.

Authors:  R H Kimberlin; C A Walker
Journal:  J Gen Virol       Date:  1978-06       Impact factor: 3.891

3.  Search for a prion-specific nucleic acid.

Authors:  Jiri G Safar; Klaus Kellings; Ana Serban; Darlene Groth; James E Cleaver; Stanley B Prusiner; Detlev Riesner
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Inactivation of prions by acidic sodium dodecyl sulfate.

Authors:  David Peretz; Surachai Supattapone; Kurt Giles; Julie Vergara; Yevgeniy Freyman; Pierre Lessard; Jiri G Safar; David V Glidden; Charles McCulloch; Hoang-Oanh B Nguyen; Michael Scott; Stephen J Dearmond; Stanley B Prusiner
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 5.  To what extent is strain variation evidence for an independent genome in the agent of the transmissible spongiform encephalopathies?

Authors:  R M Ridley; H F Baker
Journal:  Neurodegeneration       Date:  1996-09

Review 6.  Prion interference with multiple prion isolates.

Authors:  Charles R Schutt; Jason C Bartz
Journal:  Prion       Date:  2008-04-18       Impact factor: 3.931

7.  Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent.

Authors:  R A Bessen; R F Marsh
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

8.  Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification.

Authors:  Piero Parchi; Rosaria Strammiello; Silvio Notari; Armin Giese; Jan P M Langeveld; Anna Ladogana; Inga Zerr; Federico Roncaroli; Patrich Cras; Bernardino Ghetti; Maurizio Pocchiari; Hans Kretzschmar; Sabina Capellari
Journal:  Acta Neuropathol       Date:  2009-08-29       Impact factor: 17.088

9.  Resistance of bovine spongiform encephalopathy (BSE) prions to inactivation.

Authors:  Kurt Giles; David V Glidden; Robyn Beckwith; Rose Seoanes; David Peretz; Stephen J DeArmond; Stanley B Prusiner
Journal:  PLoS Pathog       Date:  2008-11-14       Impact factor: 6.823

10.  Continuous quinacrine treatment results in the formation of drug-resistant prions.

Authors:  Sina Ghaemmaghami; Misol Ahn; Pierre Lessard; Kurt Giles; Giuseppe Legname; Stephen J DeArmond; Stanley B Prusiner
Journal:  PLoS Pathog       Date:  2009-11-26       Impact factor: 6.823

View more
  25 in total

1.  Conformational transformation and selection of synthetic prion strains.

Authors:  Sina Ghaemmaghami; Joel C Watts; Hoang-Oanh Nguyen; Shigenari Hayashi; Stephen J DeArmond; Stanley B Prusiner
Journal:  J Mol Biol       Date:  2011-08-04       Impact factor: 5.469

2.  Changes in prion replication environment cause prion strain mutation.

Authors:  Nuria Gonzalez-Montalban; Young Jin Lee; Natallia Makarava; Regina Savtchenko; Ilia V Baskakov
Journal:  FASEB J       Date:  2013-05-31       Impact factor: 5.191

3.  Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice.

Authors:  Duo Lu; Kurt Giles; Zhe Li; Satish Rao; Elena Dolghih; Joel R Gever; Michal Geva; Manuel L Elepano; Abby Oehler; Clifford Bryant; Adam R Renslo; Matthew P Jacobson; Stephen J Dearmond; B Michael Silber; Stanley B Prusiner
Journal:  J Pharmacol Exp Ther       Date:  2013-08-21       Impact factor: 4.030

4.  Drug resistance confounding prion therapeutics.

Authors:  David B Berry; Duo Lu; Michal Geva; Joel C Watts; Sumita Bhardwaj; Abby Oehler; Adam R Renslo; Stephen J DeArmond; Stanley B Prusiner; Kurt Giles
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-15       Impact factor: 11.205

5.  Convergent replication of mouse synthetic prion strains.

Authors:  Sina Ghaemmaghami; David W Colby; Hoang-Oanh B Nguyen; Shigenari Hayashi; Abby Oehler; Stephen J DeArmond; Stanley B Prusiner
Journal:  Am J Pathol       Date:  2013-03       Impact factor: 4.307

Review 6.  Bioassays and Inactivation of Prions.

Authors:  Kurt Giles; Amanda L Woerman; David B Berry; Stanley B Prusiner
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-08-01       Impact factor: 10.005

Review 7.  Biology and Genetics of PrP Prion Strains.

Authors:  Sina Ghaemmaghami
Journal:  Cold Spring Harb Perspect Med       Date:  2017-08-01       Impact factor: 6.915

8.  Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo.

Authors:  Sarah K Kaufman; David W Sanders; Talitha L Thomas; Allison J Ruchinskas; Jaime Vaquer-Alicea; Apurwa M Sharma; Timothy M Miller; Marc I Diamond
Journal:  Neuron       Date:  2016-10-27       Impact factor: 17.173

Review 9.  Insights into Mechanisms of Transmission and Pathogenesis from Transgenic Mouse Models of Prion Diseases.

Authors:  Julie A Moreno; Glenn C Telling
Journal:  Methods Mol Biol       Date:  2017

10.  Guinea Pig Prion Protein Supports Rapid Propagation of Bovine Spongiform Encephalopathy and Variant Creutzfeldt-Jakob Disease Prions.

Authors:  Joel C Watts; Kurt Giles; Daniel J Saltzberg; Brittany N Dugger; Smita Patel; Abby Oehler; Sumita Bhardwaj; Andrej Sali; Stanley B Prusiner
Journal:  J Virol       Date:  2016-10-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.